Glutamate is the major mediator of excitatory synaptic transmission in the mammalian brain, 1 and accumulating evidence points to a potential role of the glutamatergic system in the pathophysiology and treatment of mood disorders. Gray et al. 2 recently reported a generalized dysregulation of glutamatergic receptors (GluRs) in the postmortem brains of depressed suicide completers, suggesting that the glutamatergic system should be considered an important mediator of psychiatric pathology and, potentially, also a common pathway for the therapeutic action of antidepressant agents. 3 To resolve this hypothesis, important information may be obtained from the target and off-target effect of commonly used antidepressants.
Glutamate is an excitatory neurotransmitter that is widely distributed in the brain, exerting its effects through the stimulation of several GluR subtypes. These include the ionotropic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), N-methyl-D-aspartate (NMDA), kainate receptors (KAR) as well as metabotropic (mGluR) receptors encoded by 24 different genes. 4 To address the question of how commonly prescribed antidepressants affect RNA expression in the glutamate system, we took advantage of an in vitro model previously shown to have a serotonergic phenotype. 5 Specifically, we treated human neural progenitor cells (NPCs) with citalopram and imipramine, and quantified expression changes of 20 GluR genes using TaqMan assays (Applied Biosystems, Foster City, CA, USA). Expression of GRIK3 was not detectable in this cell line at quantifiable levels. Antidepressants were applied at nontoxic clinically relevant concentrations of either 50 μM citalopram hydrobromide, 12.5 μM imipramine hydrochloride or no-drug control for 15 days (chronic). All numerical data are expressed as the mean ± s.e.m. Statistical differences between groups were analyzed using Student's t-test (two-tailed) followed by Bonferroni corrections for multiple comparisons. All experiments were performed in triplicates (n = 3) and (n) represents biological replicates (*Bonferroni-corrected Po0.05, # t-test P o0.05). AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; KAR, kainate receptors; NMDA, N-methyl-D-aspartate.
The NPCs employed in this study were derived from a healthy male individual. This paradigm did not allow us to test the gender differences observed by Gray et al. 2 in postmortem brains, but rather provided a gender-neutral environment from the point of view of hormones for both the treatment and the control conditions.
Citalopram, a selective serotonin reuptake inhibitor (SSRI) antidepressant, acts as a weak inhibitor in the reuptake of nonserotonergic neurotransmitters such as norepinephrine and dopamine, but as a strong inhibitor in the reuptake of serotonin. Unpaired Student's t-tests showed significant changes in RNA expression levels in 10 GluRs after the treatment with citalopram ( Figure 1a ). Metabotropic receptors (specifically GRM3, GRM4, GRM5 and GRM8) showed significantly decreased levels after citalopram treatment, whereas ionotropic receptors showed the opposite patterns with all significantly dysregulated genes being upregulated after citalopram treatment. This finding is consistent with the fact that ionotropic receptors elicit a quick response, whereas metabotropic receptors mediate a more prolonged response. Although not statistically significant, GRM7 followed the same pattern (fold change = 0.45) as the other metabotropic receptors, while there was no difference in GRM1 and GRM2. We corrected for multiple testing across the 19 t-tests performed, and only GRM4 and GRM8 met the threshold for the stringent Bonferroni method (Supplementary Table) . The studies published to date show mixed results with regard to GluRs expression changes in the depressed brain, however, findings from the largest cohort to date suggest that GluRs are largely upregulated in the depressed brain. 2 This implies the reduction of metabotropic receptors seen after citalopram treatment to be the ontarget desired effect of the antidepressant in the depressed brain.
Imipramine, a tricyclic antidepressant, acts as a strong inhibitor in the reuptake of both norepinephrine and serotonin, but also blocks histaminic, cholinergic and alpha1-adrenergic receptor sites, leading to more off-target effects than SSRIs. Unpaired Student's t-tests showed significant expression changes in 12 GluRs after the treatment with imipramine (Figure 1b) . Like with citalopram, there was an overwhelming downregulation effect with metabotropic receptors. AMPA receptors GRIA2 and GRIA4 were also downregulated. Interestingly, KAR GRIK4, GRIK5 and NMDA receptor GIN2C were upregulated after the imipramine treatment. We also corrected for multiple testing across the 19 ttests performed, and again only metabotropic receptors met the correction threshold, with significant effects in GRM3, GRM4, GRM5 and GRM8 (Supplementary Table) .
Although treatments with both drugs lead to significant decreases in metabotropic glutamate receptors, the changes were much more profound for imipramine, with as much as 95% reduction of GRM5. Interestingly, for both drugs, GRM1 and GRM2 were the least impacted (nominally significant with imipramine but less pronounced fold changes), which is perhaps expected because these receptors have overlapping function with GRM5 and GRM3, respectively. In the AMPA receptors, the two drugs induced opposite expression effects with GRIA2 and GRIA4 being downregulated by imipramine, and GRIA3 being upregulated by citalopram.
To test whether the action of citalopram and imipramine on the GluRs was dependent on the serotonin machinery, we generated stable knockdown cell lines using short hairpin RNAs against the 5-HT serotonin transporter (SERT, SLC6A4 gene) in the same background NPCs and treated these with the drugs following the same paradigm. RNA expression analysis of the most interesting receptors showed that the effects exerted by citalopram were largely dependent on the presence of the serotonin transporter, given that most of the original effects were reduced or removed (Supplementary Figure 2) . This is expected given that we achieved a partial knockdown rather than a complete knockout of SERT, 5 implying that not all effects of this pathway would be ablated.
Alternatively, the effects of imipramine remained significant, consistent with the fact that it is not a SSRI (Supplementary Figure 2) .
To test the antidepressant specificity of our findings, we quantified expression changes following the treatment with valproate, an anticonvulsant and mood stabilizer not known to have antidepressant properties. The results (Supplementary Figure 1) show wide effects on KAR and NMDA receptors, whereas essentially no effect on AMPA receptors. Interestingly, the only metabotropic receptors impacted by valproate were GRM1 and GRM2. This is the opposite of our findings with antidepressants, where the most profound effects were found in GRM3-GRM8, suggesting an alternative mechanism of action (Supplementary Figure 1, Supplementary Table) .
To our knowledge, this work constitutes the first comprehensive analysis of the effect of antidepressant treatment on the GluRs using an in vitro model with NPCs, and complements recent evidence of marked disturbances in this system. 2 Although most currently available antidepressant therapies do not specifically target the glutamate system, serotoninergic activity has been shown to alter the glutamate release. 6 Therefore, our findings are likely downstream effects, but nonetheless support the role of GluRs in the mechanisms of action of currently available antidepressants. This is also relevant as GluRs are widely expressed across the nervous system and especially across brain regions implicated in depression, like the frontal cortex, the anterior cingulate cortex, the hippocampus and the thalamus. 2, 3, 7, 8 Future studies will be warranted to extend our understanding of these mechanisms.
